Skip to main content
Clinical Trials/DRKS00016158
DRKS00016158
Recruiting
N/A

Genetic screening of an at-risk population for Hereditary TransthyRetin-related AMyloidosis and longitudinal monitoring of TTR positive subjects - TRAMmoniTTR

Centogene AG Rostock0 sites5,000 target enrollmentMarch 12, 2019

Overview

Phase
N/A
Intervention
Not specified
Conditions
Not specified
Sponsor
Centogene AG Rostock
Enrollment
5000
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 12, 2019
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Centogene AG Rostock

Eligibility Criteria

Inclusion Criteria

  • Informed consent is obtained from the participant
  • The participant has no diagnosis of alcoholism according to international guidelines
  • The participant has not undergone chemotherapy for any carcinoma
  • The participant is at risk for hATTR due to two or more the factors listed below:
  • \- cardiomyopathy or polyneuropathy with no obvious etiology
  • \- atypical Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) or Motor Neuron Disease (MND)
  • \- autonomic dysfunction
  • \- hypertrophic cardiomyopathy or heart failure with preserved ejection fraction Left Ventricular Hypertrophy (LVH)
  • \- bilateral carpal tunnel syndrome
  • \- spinal stenosis or spinal radiculopathy

Exclusion Criteria

  • Informed consent is not obtained from the participant
  • The participant is younger than 18 years of age
  • The participant has a diagnosis of alcoholism according to International guidelines
  • The participant has undergone chemotherapy for any carcinoma
  • The participant is not at risk for hATTR

Outcomes

Primary Outcomes

Not specified

Similar Trials